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1 Introduction  
1.1 Myocardial infarction 
1.1.1 Definitions 
The pathological definition of myocardial infarction (MI) is myocardial cell death due to 
prolonged ischemia [1]. This ischemia is almost always caused by a sudden reduction in 
coronary blood flow because of atherosclerosis with superimposed thrombosis, with or 
without concomitant vasoconstriction [2]. MIs are classified by (1) size – microscopic (focal 
necrosis), small (<10% of the left ventricle), medium (10–30% of the left ventricle) or large 
(>30% of the left ventricle), (2) localization – anterior, lateral, inferior, posterior, septal or a 
combination thereof, and (3) phase – acute (6 h to 7 days), healing (7–28 days) and healed 
(>28 days). Clinicians additionally classify MIs according to electrocardiography (ECG) 
criteria to determine if there is ongoing ischemia (ST-segment elevation, ST-segment 
depression or T-wave abnormality in two contiguous leads) or established MI (abnormal Q 
wave in the frontal plane leads or in leads V4–V6 and/or a QR wave longer than 30 ms in 
leads V1–V3). However, not all patients who develop myocardial necrosis exhibit ECG 
changes either acutely or chronically. In such cases the MI might be too small to produce 
ECG changes, or the changes are hidden within QRS confounders such as a bundle-branch 
block, left ventricular hypertrophy, Wolff-Parkinson-White syndrome or previous MI [1]. In 
everyday clinical practice, MIs are categorized according to ECG findings into ST-segment 
elevation and non-ST-segment elevation in the acute phase and into Q-wave MI and non-Q-
wave MI in the subacute phase.  
Since 2000, the clinical definition of acute or recent MI, in Norway and other countries, 
has been primarily based on biochemical markers of myocardial necrosis (Fig. 1) [1;3]. 
However, a previous definition of acute MI prevailed when the patients were included in the 
present study (Fig. 1) [4].  
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Current definition of 
myocardial infarction (MI)
1) Typical rise and graduate fall (troponin) or more 
rapid raise and fall (CK-MB) of biochemical 
markers of myocardial necrosis with at least one of 
the following:
a) Ischemic symptoms;
b) Development of pathologic Q wave on the 
ECG;
c) ECG changes indicative of ischemia (ST 
segment elevation or depression); or
d) Coronary artery intervention (e.g., coronary 
angioplasty).
2) Pathological findings of an acute MI
Criteria for acute evolving, or recent MI
Either of the criteria satisfies the diagnosis or acute, 
evolving, or recent MI:
Definition of myocardial 
infarction per 1999
1) Retrosternal pain with radiation to neck, arms, or 
abdomen independent of respiration. Duration at 
least 20 minutes and no or just transient effect of 
nitroglycerine. 
Accompanying symptoms are:
Nausea, vomiting, cold sweat, anxiety, and 
dyspnoea or syncope/cardiac arrest.
2) ST segment elevation in one or more leads. 
Negative T wave development. After few hours 
up to 1 – 3 days development of Q waves with 
transmural infarction. New left (or right) bundle 
branch block together with typical clinical signs.
3) Creatinin kinase (CK) above 200 U/l for men and 
150 U/I for women. Creatinin kinase MB fraction 
(CK-MB) over10 μg/l.
Two out of three of the following criteria:
 
Figure 1 Current and previous clinical definitions of MI [1;3;4] 
 
 
1.1.2 Epidemiology 
Coronary artery disease (CAD) is a pandemic causing more than 7 million deaths each year, 
and thus is the most common cause of death worldwide [5]. While the number of deaths from 
CAD has declined in North America, Australia and many Western European countries over 
recent decades, there has been an analogously strong increase in death rates from CAD in 
many Eastern European countries. In addition, CAD is one of the most important causes of 
loss of future disability-free life as quantified by DALYs (disability-adjusted life years), and 
is in the same range as HIV infections, stroke and unipolar depressive disorders [6]. The 
World Health Organization (WHO) has estimated that CAD accounts for 10% of DALYs lost 
in low- and middle-income countries and 18% in high-income countries [5].  
The number of deaths from cardiovascular diseases (CVDs) and MI is declining in 
Norway. Statistics Norway reported that approximately 20,100 people died annually from 
CVDs during the period 1971–1975, accounting for 51% of the total number of deaths, with 
this figure declining to approximately 17,400 annually for the period 2001–2003, accounting 
for 40% of the total deaths [7]. From 1996 to 2003 the number of patients who died from 
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acute MI also declined in Norway, from 5,771 in 1996 to 4,763 in 2003, accounting for 13% 
and 11% of the total deaths, respectively [8;9].  
There are no reliable data on the incidence of MI in Norway. However, data from the 
Norwegian Patient Register, which records all hospital admissions, show that the number of 
admissions for acute MI declined by 18% between 1991 and 2000, from 14,457 to 11,892 
[10], whereas the number of admissions among patients 80 years or older increased. New 
diagnostic criteria for acute MI were established in Norway in 2000 (Fig. 1), which resulted 
in the total number of hospital admissions for acute MI increasing by 33% between 2000 and 
2002, to 15,829 [1;11].  
Several factors make it difficult to establish the true natural history of an acute MI, 
including the high frequency of silent infarction, the high frequency of acute coronary deaths 
outside hospital and the diverse methods used to diagnose the condition. Community studies 
have shown that the overall mortality rate of acute heart attacks is 30–50% within the first 
month, with about half of these deaths occurring during the first 2 hours [12;13]. This high 
rate of initial mortality has changed only slightly during recent decades [14], whereas there 
has been a profound fall in the case-fatality rate amongst those treated in hospital. In the 
1960s, the in-hospital mortality was about 25–30% [15]. In 1993, the in-hospital mortality 
was 18% in an unselected Norwegian MI population. In the present study, the in-hospital 
mortality of our patients recruited in 1999 from the same hospitals as in 1993 plus a few 
additional hospitals was 15% [16;17]. Two recent publications from the Worcester Heart 
Attack Study stated that while in-hospital deaths after MI decreased from 20% between 1975 
and 1978 to 12% in 2001, the 1-year crude case-fatality rate of patients discharged alive after 
MI increased from 14% between 1975 and 1978 to 20% in 2001 [18;19]. However, after 
adjusting for age, sex and cardiovascular comorbidity, the increase was not statistically 
significant [19].  
From 4% to 12% of the decline in CAD mortality rates has been attributed to the initial 
treatment of MI, while 23–46% of the decline being attributed to all medical and surgical 
therapies [20-23]. The WHO MONICA (Monitoring Trends and Determinants in 
Cardiovascular Disease) project monitored trends in CAD over 10 years in 21 countries. In 
MONICA populations in which CAD mortality decreased, reduction in coronary events were 
responsible for two-thirds of the decrease, with reduction in case fatalities accounting for the 
other third [13]. While mortality from CAD has declined, the number of hospital admissions 
has increased, which is mainly due to chronic manifestations of CAD producing a growing 
population of patients whose lives are affected by symptomatic CAD [24]. 
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1.1.3 Sequelae after MI 
MI patients are at risk of subsequently experiencing one or more sequelae such as malignant 
arrhythmias, reduced left ventricular function, angina pectoris and psychological reactions, 
particularly depression. Patients are at a high risk of sudden cardiac death due to malignant 
ventricular arrhythmias within 1–2 years of an MI [25]. Two patterns of fatal arrhythmias 
have been identified in patients with ischemic heart disease: (1) ventricular tachyarrhythmias 
triggered by acute myocardial ischemia in patients with or without preexisting myocardial 
scarring, and (2) ventricular tachyarrhythmias related to an anatomical substrate (usually 
scarring from a previous infarction) without active or clinically evident myocardial ischemia 
[26]. Epidemiological data suggest that 80% of fatal arrhythmias are caused by structural 
arterial abnormalities and their consequences [26].  
Reduced left ventricular function and overt heart failure (HF) due to the loss of viable 
myocardial tissue are common consequences of MI, but in some patients HF is caused by 
acute mitral regurgitation, arrhythmias, cardiac stunning or diastolic dysfunction of the left 
ventricle [27]. The presence of left ventricular dysfunction or HF indicates a graver 
prognosis, even when it presents only transiently [27]. A recent review found that 30–40% of 
acute-MI patients experience HF at some time following hospital admission for the MI [28]. 
This is in accordance with estimated numbers in a UK study [27]. In a study including all 
patients with MI in a community from 1979 to 1998, 41% of the patients without previous 
chronic HF experienced episodes with HF [29]. Among patients experiencing episodes of HF 
after their MI, 59% had their episodes within the first 30 days after the MI, 9% within the 
next 11 months, and 32% thereafter [29]. The median survival in patients who experienced 
episodes of HF was 4 years, and this did not improve for patients included during the last 
years of inclusion compared with patients included earlier, even after adjustment for baseline 
characteristics [29]. Also, the Worchester Heart Attack study found that the mortality rate 
was 50% higher in patients with known chronic HF and in those who had HF as a 
complication to the index MI [19]. On the other hand, in the Framingham study 5-year case 
fatality from HF independent of aetiology, decreased in both men and women from 70% and 
57 %  respectively in 1950 – 69 to  59% and 45% in 1990-99 [30].   
There is less information on the prevalence and incidence of left ventricular systolic 
dysfunction after MI without manifest HF. A French MI-register study revealed that 52% and 
46% of patients had a left ventricular ejection fraction (LVEF) of ≤50% within 5 days of an 
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MI in 1995 and 2000, respectively [28]. Screening data from clinical trials performed during 
1990–2002 showed that approximately one-third of MI patients had an LVEF of ≤40% 
during the first week after MI [28]. Left ventricular systolic dysfunction observed after an MI 
is one of the most important predictor of mortality following MI. The GISSI-2 (Gruppo 
Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) study found that the 6-
month mortality was almost 10-fold higher in patients with an LVEF of <40% (60 out of 569 
patients died) than in patients with an LVEF of ≥50% (18 out of 1672 patients died) [31]. 
This difference had not changed since the prethrombolytic era, emphasizing the importance 
of interventions aimed at minimizing left ventricular damage [32].  
Whilst the LVEF is inversely correlated with the risk of developing HF after MI, there 
is evidence that left ventricular systolic dysfunction and the occurrence of HF are both 
independent predictors of mortality after MI. One study found that the 1-year all-cause 
mortality in patients with in-hospital HF after MI was 8% in patients with a normal LVEF, 
19% in patients with an intermediate LVEF and 26% in patients with a reduced LVEF, while 
the corresponding numbers for the same LVEFs were 3%, 6% and 12%, respectively, in 
patients without in-hospital HF after MI [33]. 
Chest pain or angina pectoris is the core symptom of CAD. The prevalence of angina 
pectoris in Western countries is estimated to be 2–4% in people aged 45–74 years, but these 
estimates are based largely on studies performed between 1970 and 1985 [34]. The GUSTO-I  
(Global Utilization of Streptokinase and t-PA for Occluded coronary arteries) trial found that 
the incidence of in-hospital post-infarction angina pectoris was 20% [35]. One study found 
that 56% of men and 63% of women had experienced chest pain during heavy physical 
exercise within 1 year of an MI, with 21% and 28% experiencing chest pain at rest [36]. In a 
follow-up study that applied the Rose angina questionnaire [37], 22% of patients reported 
angina and only 44% reported no chest pain within 4 years of an MI [37;38]. The patients in 
these two studies had their index MI 13 to 20 years ago [36-38]. The annual mortality rate in 
patients with stable angina pectoris has been estimated from clinical trials at 0.9–1.4% [34]. 
This is in accordance with registry data indicating an annual cardiac mortality rate of 1.5% in 
stable, medically treated patients with CAD [39]. However, the death rates were two- and 
fivefold higher in patients with one and more than one previous MI, respectively, than in 
those with no previous MI [39].  
Approximately 20% of patients experience major depression after MI, with another 
20% experiencing minor depression [40]. Two recent meta-analyses concluded that both the 
short- and long-term total mortality is higher in depressed patients with MI or CAD than in 
  6 
non-depressed patients [41;42]. The mechanism underlying this increased mortality is 
unclear, but theories include both biological and behavioral mechanisms, such as 
cardiotoxicity of antidepressant drugs, more major cardiac risk factors, more severe coronary 
disease in depressed patients, reduced adherence to medical treatment, altered cardiac 
autonomic tone, greater platelet activation, inflammatory processes and an unhealthy 
lifestyle, including physical inactivity, unhealthy diet and smoking habits [43;44]. It is not 
known whether treating depression in patients with CAD will improve cardiovascular 
outcomes. However, treatment is important in order to relieve psychological, social and 
functional impairments [44].  
 
1.1.4 Interventions 
During the last 2–3 decades, several new medical and surgical interventions have increased 
survival and function in patients with MI. Beta blockers limit the infarct size, reduce life-
threatening arrhythmias and relieve pain in patients with acute MI [45]. A meta-analysis of 
82 trials showed that beta blockers did not reduce all-cause mortality within 6 weeks after an 
MI (odds ratio (OR)=0.96, 95% confidence interval (CI)=0.85–1.08) but did significantly 
reduce long-term all-cause mortality (OR=0.77, 95% CI=0.69–0.85) [46], with the effect 
being highest in patients older than 65 years [47].  
Platelets are important in the formation of the thrombus that is superimposed on the 
atherosclerotic plaque in an acute MI. Currently available antiplatelet drugs, such as 
acetylsalicylic acid and clopidogrel, interfere with certain steps in the activation process of 
platelets, including adhesion, release and/or aggregation, and thus prevent the formation of 
the thrombus [48]. A meta-analysis of patients with an acute MI showed that 1 month of 
antiplatelet therapy reduced the incidence of vascular events (MI, stroke or vascular death) by 
38 (standard error (SE)=5) (p<0.0001) per 1000 treated patients, and total mortality by 24 
(SE=4) (p<0.0001) per 1000 treated patients [49]. In patients with previous MI with a mean 
treatment duration of 2 years, the corresponding mean reductions were 36 (SE=5) (p<0.0001) 
per 1000 treated patients for all vascular events and 12 (SE=5) (p=0.02) per 1000 treated 
patients for total mortality [49].  
Thrombolytic therapy in acute MI aims at restoring coronary flow by recanalizing the 
thrombotic occlusions associated with the MI and thereby reducing the infarct size, 
improving in myocardial function and in the chances of survival. Thrombolytic therapy is 
indicated in MI patients with ST-segment elevation or newly developed left-bundle-branch 
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block (without contraindications) presenting within 12–18 hours of symptom onset [4]. A 
systematic review of the effect of thrombolytic treatment on mortality in nine trials, each of 
which included more than 1000 patients with suspected MI, revealed highly significant 
reductions in 5-week mortality of 30 per 1000 treated patients in patients presenting within 0–
6 hours after onset and of 20 per 1000 in patients presenting within 7–12 hours, and a 
statistically uncertain reduction of 10 per 1000 in those presenting at 13–18 hours after onset 
[50]. An analysis of the 10-year survival of the ISIS-2 (Second International Study of Infarct 
Survival) patients found that early survival advantages produced by thrombolytic therapy in 
acute MI were maintained for at last 10 years [51].  
Percutaneous coronary intervention (PCI) is the process of catheter mediated 
angioplasty, usually with a balloon, in a narrowed or occluded coronary blood vessel with or 
without the placement of a stent. Randomized clinical trials in MI patients with ST-segment 
elevation comparing timely preformed primary PCI (e.g. intervention in the culprit vessel 
within 12 h after the onset of symptoms) with thrombolysis have shown more effective 
restoration of patency, less reocclusion, improved residual left ventricular function and better 
clinical outcome [52]. In a meta-analysis of 23 randomized trials primary PCI was more 
effective than thrombolysis in preventing short time death (7% vs. 9%, p=0.0002) and non-
fatal reinfarction (3% vs. 7% p<0.0001) and the results persisted during long-term follow-up 
[53]. Routine coronary stent implantation in patients with acute myocardial infarction 
decreases the need for target-vessel revascularization but is not associated with significant 
reductions in death or reinfarction rates when compared with primary angioplasty [52]. Also 
in patients with non-ST-segment elevation acute coronary syndrome (ACS) early coronary 
angiography including PCI when possible and indicated is beneficial compared to selective 
performance of angiography based on clinical course [54]. A meta-analysis of the most 
contemporary trials has confirmed this showing a long-term benefit in terms of both death 
(RR (risk ratio) 0.75 CI 0.62–0.92) and new MI (RR 0.75 CI 0.62–0.91) [55]. 
Coronary artery bypass graft surgery (CABG) prevents death, irreversible myocardial 
damage and malignant arrhythmias, and relives angina symptoms. These benefits have been 
documented in patients with main left coronary artery stenosis, in patients with significant 
stenosis in the proximal part of the left anterior descending artery and one other segment of 
the other coronary artery domains and when one or more segment are affected in all three 
coronary artery domains [56-58]. 
Angiotensin-converting enzyme (ACE) inhibitors competitively block conversion of 
angiotensin-I into angiotensin-II and reduce the breakdown of bradykinin, producing 
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haemodynamic, neurohormonal, antiproliferative, natriuretic and antiatherogenic effects, 
many of which are important when treating patients with CAD and HF [59]. There have been 
two types of studies of ACE inhibitors in MI: (1) early-intervention trials, with initiation of 
ACE inhibitors within 24–36 hours after the MI, and (2) late-intervention trials, with 
initiation later than 48 hours after the MI.  
A meta-analysis including patients from the early-intervention studies revealed that the 
30-day mortality was lower for treated patients than placebos (7.1% vs. 7.6%) (p<0.004) 
equaling 5 lives saved per 1000 patients treated for 4–6 weeks [60]. This was due to a more 
pronounced effect in patients presenting with HF or anterior MI. Early treatment with ACE 
inhibitors also protected against non-fatal HF after the MI (14.6% vs. 15.2%) (p=0.01) [60].  
Late-intervention studies have included patients with a reduced LVEF or HF, who 
constitute a high-risk group. A meta-analysis of these studies with a mean follow-up of 2.6 
years revealed a reduction in mortality compared with placebos (23.4% vs. 29.1%), 
corresponding to 57 deaths prevented per 1000 patients treated for 2.5 years [61]. Secondary 
prevention after MI in patients without HF has also been studied. Two of the largest studies, 
HOPE (Heart Outcomes Prevention Study) and EUROPA  (European Trial on Reduction of 
Cardiac Events with Perindopril in stable Coronary Artery Disease), found that the primary 
end points (HOPE: death from cardiovascular causes, MI or stroke; EUROPA: cardiovascular 
mortality, MI or sudden death) were reduced by 38 per 1000 patients treated for 5 years in the 
HOPE study and by 50 per 1000 patients treated for 4.2 years in the EUROPA study [59].  
The 4S study (Scandinavian Simvastatin Survival Study) was the first to clearly 
demonstrate the benefits of statins after MI [62]. In the 4S study, the mortality was lower in 
patients treated with statins than in controls (8% vs. 12%), corresponding to 33 lives saved 
per 1000 patients treated for 5.4 years [62]. A recent meta-analysis showed that the effect of 
statins on major vascular events was proportional to the achieved reduction in LDL 
cholesterol [63]. The PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) 
study also has shown the benefit of statins in the elderly [64]. In patients aged 70–82 years, 
the composite end point of coronary death, non-fatal MI and stroke was reduced in patients 
with known CVDs compared to controls (17% vs. 22%), corresponding to a reduction of 43 
events per 1000 patients treated [64]. 
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1.1.5 Outcomes in MI 
The ultimate and traditionally used measure of outcome in cardiovascular research is 
cardiovascular and total mortality. Composite end points such as mortality plus events or 
event-free survival have also been used, especially when a low mortality rate is expected. 
Events other than death can include both cardiac and cerebrovascular incidents, and 
sometimes also hospitalization due to deterioration of a chronic condition. The observed 
decrease in cardiovascular mortality and increase in admission rates for chronic conditions 
such as HF and CAD suggests that the longer survival of patients with heart diseases 
contributes to a growing population of patients at increased risk of subsequent cardiovascular 
complications [24]. This group of patients needs to be evaluated with outcome measures 
other than mortality alone in clinical trials, epidemiological research and other observational 
studies. Possible outcomes other than death include return to work, the New York Heart 
Association (NYHA) Functional Classification, chest pain on the Canadian Cardiovascular 
Society (CCS) Functional Classification, functional status, and measures of health status and 
quality of life [65;66]. The European Society of Cardiology has included maintenance and 
improvement of quality of life as treatment goals in their guidelines, both for patients with 
chronic HF and those with stable angina pectoris [34;67]. 
 
 
1.2 Health-related quality of life 
1.2.1 Concepts and definitions 
In 1948 the WHO defined health as “…a state of complete physical, mental and social well-
being, and not merely the absence of disease and infirmity” [68]. The concept of quality of 
life lacks a formally agreed definition, but it is clearly complex, abstract and 
multidimensional. Quality of life is distinct from (but related to) health, and many attempts to 
define quality of life have been based on the WHO definition of health [69;70]. The quality 
of life assessment group of the WHO defines quality of life as “the individual’s perception of 
their position in life in context of the culture and value system in which they live and in 
relation to their goals, expectations, standard, and concerns” [71]. Other published definitions 
include “…those aspects of life and human function considered essential for living fully” [72] 
and “…an individual’s satisfaction with life in domains he or she considers important” [73]. 
It is clear that quality of life means different things to different people, and has different 
meanings depending on the area of application. Some have argued that, at least in Western 
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countries, people intuitively understand the factors influencing quality of life, and thus no 
formal definition is needed [69]. 
Attempts to distinguish between quality of life in the more general sense (often referred 
to as the overall quality of life) and quality of life related to the requirements of clinical 
medicine and medical research have led to the introduction of the “health-related quality of 
life” (HRQoL) [69]. Several definitions of HRQoL have been proposed. A popular definition 
is that by Wenger and Furberg [74]: “Those attributes valued by patients, including: their 
resultant comfort or sense of well-being; the extent to which they are able to maintain 
reasonable physical, emotional, and intellectual function; and the degree to which they retain 
their ability to participate in valued activities within the family, in the workplace, and in the 
community.” A consensus conference in the early 1990s agreed upon the fundamental 
dimensions essential to HRQoL assessment [75]. As primary dimensions they suggested 
physical functioning, social functioning, psychological functioning, overall life 
satisfaction/well-being and perception of health status, with additional dimensions including 
intimacy, sexual functioning, sleep disturbance, pain and symptoms.  
The term health status refers to the level of wellness and illness, taking into account the 
presence of biological or physiological dysfunction, symptoms and functional impairment. 
Bergner distinguished between health status and quality of life [76], although health status is 
often used interchangeably with HRQoL [70]. 
 
1.2.2 Measures for assessing HRQoL 
One of the main interests in this field has been developing measurement instruments [77]. 
There are three principal types of HRQoL measures: generic, disease-specific and domain-
specific instruments [69;78]. Generic instruments are meant for general use, irrespective of 
the illness or condition of the patient, and often are also applicable to healthy people [69]. 
The advantage of generic instruments is that scores can be compared across different patient 
groups and with general-population norms. Generic instruments are supposed to cover the 
main dimensions of HRQoL and commonly include items that explicitly inquire about the 
overall quality of life [69].  
Disease-specific instruments cover all or most of the main dimensions of HRQoL whilst 
focusing on the issues of particular concern to patients with specific diseases or groups of 
diseases. The criteria used to assess outcomes vary between diseases. Disease-specific 
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HRQoL instruments are needed to ensure sensitivity to small but clinically significant 
changes in health status and to levels of disease severity [78].  
Domain-specific instruments are instruments that explore particular issues in greater 
depth without aiming to cover all the main dimensions of HRQoL [69;78], such as pain, 
depression, anxiety, fatigue and coping.  
 
1.2.3 Properties of HRQoL instruments 
Transferring an HRQoL instrument from one country to another with a different language 
and culture requires formal translation and adaptation, which can be accomplished in several 
ways. One recommended process is to first translate and back-translate the instrument 
according to an accepted procedure, and then test an agreed translation in the new 
environment [79;80]. This elaborate translation process aims to avoid introducing errors into 
the questionnaire or shifts in nuances that might affect the way patients respond to items, with 
the subsequent test designed to show that the translated version is equivalent to the original 
instrument.  
 
1.2.3.1 Reliability 
The reliability of a measurement instrument refers to the extent to which it yields the same 
result on repeated trials [81]. Reliability in HRQoL studies can be assessed in different ways. 
First, the test–retest reliability refers to the extent to which an instrument gives the same 
score when applied at different times, on the assumption that the quality of life of 
investigated individual has not changed in the intervening periods [81]. It is also used to refer 
to whether the measurement tool gives the same results when administered to two individuals 
with the same HRQoL. The test–retest design produces relevant information on instrument 
reliability when it is likely that the characteristics of the person being assessed have not 
changed. Conventionally, to minimize recall bias, reliability is assessed using a test and retest 
separated by up to 4 weeks.  
Second, the internal consistency reliability refers to the degree of homogeneity of items 
in an instrument or scale. This denotes the extent to which responses to the various 
components of the instrument correlate with one another or with a score on the instrument as 
a whole (either including or excluding the items in question). The presence of a strong 
correlation between these elements suggests that they are measuring the same or closely 
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related constructs in a reliable manner, whereas a weak correlation suggests that the construct 
is not being measured reliably and that there are sources of unexplained error in the 
measurement. Internal consistency reliability is most often quantified using Cronbach’s alpha 
[80-82].  
The minimal levels of reliability considered necessary vary with the specific 
application. As a general rule, reliabilities should be at least 0.80 for widely used scales [81], 
with the reliability and precision of the measurement increasing when the decision is more 
critical [79;80].  
 
1.2.3.2 Validity 
The validity of a measurement instrument does not refer to the instrument itself, but to 
whether particular interpretations of its scores are well-justified. It is only meaningful to 
consider the validity of a specified purpose or interpretation of the resulting scores. The 
inferences that may be made from the score for a given instrument vary with the situation in 
which it is applied, and hence the validity of each inference must be established [83].  
An overall assessment of the utility and limitations of a measurement instrument is 
gradually built up from cumulative evidence about interrelationships among the content of 
the instrument and definitions of the construct to be measured, and interrelationships among 
scores and results of other relevant measurements. Typically, this process involves 
comparisons of measurements made in cross-sectional and longitudinal studies, frequently 
before and after a certain intervention. 
Some authors have divided validity into three distinct categories, as listed below, while 
others have considered many different attributes, and the terminology is diverse [80]. 
Distinguishing between different types of validity is often not useful, and so validation can be 
considered a process of hypothesis testing without the traditional division into distinct types 
of validity [80]. However, the various types of validity all address the degree of confidence 
that can be placed on inferences drawn from scores obtained on scales [80].  
We now present a traditional typology of validity, content validity, construct validity and 
criterion-related validity, based on several previous reports [69;80;81]. Content validity is the 
extent to which the items in the instrument are linked by a plausible rationale to some 
particular conception of the construct being measured, such as the quality of life. This is 
normally based on the judgment of the developers, experts or users of the instrument.  
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Construct validity comprises several types of validity. Information on the internal 
statistical structure of an instrument is relevant to the interpretation of its scores. Other types 
of evidence sought include relationships of scores with other variables. Evidence supporting 
particular interpretations may come from findings of similar results (convergence) or 
dissimilar results (divergence), depending on the variables involved.  
For HRQoL instruments, it is frequently assumed that a more severe disease is, on 
average, associated with a lower quality of life. Similarly, it can be expected that a treatment 
that is already known to reduce the severity of a disease or its symptoms will be associated 
with an improved quality of life [83]. 
Hence, correlations between scores on an HRQoL instrument and variables representing 
other clinical indicators such as use of medication, reported chest pain or the LVEF might be 
examined. Alternatively, differences in HRQoL scores can be compared between treated and 
untreated subjects. It is expected that, on average, scores on the HRQoL instrument will be 
correlated with or show differences or changes in the expected direction in concert with 
clinical markers or disease severity and with other health status measures [83].  
Criterion-related validity represents evidence of validity by showing relationships 
between scores and criterion variables. Selecting a single criterion variable as a gold standard 
is difficult for quality of life instruments, due to the subjective nature of the construct. If the 
criterion variable exists at the same time as HRQoL is measured, the criterion validity is 
called concurrent validity. Predictive validity, on the other hand, refers to a future criterion 
[81]. Validating an instrument is an ongoing process since a single relationship is normally 
insufficient to conclusively establish the validity of a given interpretation. 
 
1.2.4 Theoretical models linking biochemical, physiological and clinical 
variables with HRQoL 
A conceptual model is needed as a foundation for the construct of HRQoL and to explain the 
relationships among these components [77]. A sound theoretical model would assist the 
selection of measures for use in clinical studies by allowing the critical evaluation of both the 
validity and usefulness of the instruments. A clear theory would also allow hypotheses about 
the relationship between patient characteristics, the intervention and the outcome to be tested, 
so as to detect possible confounding. A theoretical model would also facilitate the use of 
HRQoL measures as a primary outcome by allowing specific hypotheses to be made about 
which components of the model are expected to respond to interventions [77]. 
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Some work has already been done in this field. Wilson and Cleary have presented a 
theoretical framework linking HRQoL with clinical variables [70]. This model, presented in 
Fig. 2, suggests that health exists on a continuum with of increasing, social and psychological 
complexity. Each step in the model from symptom status is again affected by characteristics 
and environment of the individual patient.  
 
Biological and 
Physiological 
Variables
Symptom 
Status
Functional 
Status
General 
Health 
Perceptions
Overall 
Quality of 
Life
Characteristics of 
the Individual
Characteristics of 
the Environment
Non-medical
Factors
Symptom 
Amplification
Personality
Motivation
Values
Preferences
Psychological
Supports
Social and
Economic
Supports
Social and
Psychological
Supports
 
Figure 1  Conceptual model relating HRQoL with other patient outcome measures. From Wilson and 
Cleary [70] 
 
 
 
For heart patients, biological and physiological variables include results from clinical 
examinations, including auscultation of the heart, laboratory results including serum markers 
of cardiac damage, echocardiographic parameters, other cardiac imaging techniques and 
ECG. Symptoms are the perceptions of patients of an abnormal physical, emotional or 
cognitive state [70]. Cardinal symptoms of heart disease include chest pain or discomfort, 
syncope, collapse, palpitation, dyspnoea, oedema, cough, haemoptysis and excess fatigue 
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[84]. Emotional symptoms such as anxiety and depression are also often associated with 
cardiac diseases [36].  
Functional status is the ability of an individual to perform normal daily activities, fulfill 
usual roles, and maintain health and well-being [70;85]. The two most used functional scales 
in cardiovascular patients are the CCS Functional Classification, which assesses function in 
relation to chest pain, and the NYHA Functional Classification, which assesses function in 
relation to any symptom related to the cardiovascular system (e.g. fatigue, palpitation, 
dyspnoea or chest pain) [65;66]. Four commonly measured domains of functioning are 
physical, social, role and psychological [70].  
General health perceptions represent the integration of all the above-mentioned health 
concepts as well as others such as mental health, and they are by definition subjective ratings 
[70]. General health perceptions have been found to be strongly correlated with the use of 
general medical services, somatization and hypochondrias [70;86]. However, the concept has 
also been found to be a strong predictor of survival. One example is a study on 10-year 
survival in patients with MI, CABG surgery or PCI, which found that the score for subjective 
general health 1 year after the index event was the strongest predictor of death within 
10 years, with a risk ratio >3 when the score differed by 1 on a scale from 1 to 4, which is 
about twice that of any other dimensions of quality of life [87].  
Overall quality of life is assumed to represent a stable synthesis of a wide range of 
experiences and feelings that people have. As such it should be related to HRQoL and to 
other salient life circumstances, experiences and feelings [70]. However, the correlation 
between overall quality of life and objective life status is weaker than anticipated, which 
might be due to accommodation to illness, changes in internal standards or values, or to 
conceptualization of the overall quality of life catalyzed by a change in health state [88;89]. 
 
 
1.3 HRQoL after MI 
1.3.1 Assessment of HRQoL in patients with MI 
The most commonly generic instruments applied to patients with MI are the Sickness Impact 
Profile (SIP), the Nottingham Health Profile (NHP), and the Short Form 36 (SF-36) and its 
shorter versions the SF-12 and SF-8 [90-95]. An assessment of patients with CAD using the 
SIP, NHP and SF-36 concluded that the SF-36 was the most reliable, valid and sensitive 
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instrument for assessing the quality of life [96]. Both the SF-36 and SF-12 have shown high 
validity and reliability in patients with CAD [97;98]. The EuroQol (EQ-5D) index has also 
shown high validity and reliability in CAD patients, and is increasing in popularity [99-101].  
Some of the most commonly used disease-specific HRQoL instruments for MI, angina 
or HF in recent years have been the MacNew Quality of Life after Myocardial Infarction 
questionnaire (MacNew QLMI), the Seattle Angina Questionnaire (SAQ), the Minnesota 
Living with Heart Failure Questionnaire (MLHF) and the Kansas City Cardiomyopathy 
Questionnaire (KCCQ) [102-106]. All of these instruments have documented validity and 
reliability [106;107]. However, a direct comparison revealed that angina grades could be 
discriminated better with the MacNew QLMI questionnaire than with the SAQ, although the 
SAQ was more responsive to longitudinal changes over time [108]. Moreover, the KCCQ has 
been found to be more responsive to changes than the MLHF [106].  
 
1.3.2 Effect of MI on subsequent HRQoL 
A systematic review of the quality of life after MI concluded that HRQoL is minimally 
affected by an MI [109], although the authors stated that this might have been due to the 
measurement tools not being sensitive enough. Moreover, this result contrasts the findings in 
population-based studies [110-112]. One such study measured HRQoL in the same 
population over a 5-year interval, during which 62 of 10 618 subjects developed CAD (60% 
unstable angina or MI) [102]. The decline in HRQoL between the two measurements was 
significantly more pronounced in subjects who developed CAD than in 310 controls without 
CAD on four out of eight SF-36 scales. In another population-based study, 89 of 8 723 
patients developed MI, and measures of HRQoL using a specially designed instrument 
showed that premorbid HRQoL in patients who later developed MI was comparable to the 
age-adjusted population norms [112]. Three assessments of HRQoL during the 12 months 
immediately following the MI revealed a monotonic decrease in HRQoL. The changes were 
most pronounced for physical functioning, but statistically significant also for social 
functioning, role functioning, anxiety and depression symptoms. In a third study, patients 65 
years or older underwent repeated measurements of HRQoL [111]. Patients who had an MI 
between the measurements were more likely to experience a decline in HRQoL. Several 
studies also found that HRQoL scores still were lower from 1 to 5 years after the MI than 
general-population norms based on both the SF-36 and the NHP [38;113-115].  
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In a study comparing HRQoL between different patient groups, the SF-36 scores in 
patients with cardiovascular conditions were comparable to those in patients with cancer, 
endocrine diseases, visual impairments and chronic respiratory diseases, but not as bad as 
those in patients with gastrointestinal conditions, cerebrovascular/neurological conditions, 
renal diseases or musculoskeletal conditions [116]. When comparing between different 
cardiovascular diagnoses, the impairment in HRQoL was reportedly greater in patients with 
HF than in patients with other heart conditions such as angina pectoris and those with a 
history of MI [112;117].  
 
1.3.3 Determinants of HRQoL after MI 
A review of the quality of life after MI based on literature published between 1985 and 1999, 
which included 11 studies that assessed HRQoL from 4 months to 5 years after the index MI 
[109], found that the severity of MI-related symptoms, the age of the patient and the timing of 
HRQoL measurement after MI had the greatest effects on HRQoL after MI. Subsequent 
studies using the SF-36 or SF-12 have identified employment status, symptoms, 
manifestations of CAD other than MI, additional comorbidity, depression and baseline 
HRQoL as important determinants of later HRQoL [114;115;118-121].  
Whether sex is a determinant of HRQoL after MI remains debatable, given that several 
studies have demonstrated a sex difference in HRQoL after MI while others have not 
[36;114;115;118;119;121-130]. Also, one study found that social support was an important 
determinant for HRQoL in patients with angiographically verified CAD [131].  
The identified determinants vary between studies due to differences in patient selection, 
time interval between MI and the survey of HRQoL, the potential predictors included and the 
chosen measures of HRQoL.  
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2 Aims of the study 
The long-term course of MI has changed in recent decades, with a substantially increased 
survival leading to the need for additional outcome measures in patients with MI. HRQoL has 
proved useful for measuring the outcome after MI when following up patients with CAD. A 
better understanding of HRQoL in cardiac diseases is crucial, as is the need for adequate and 
well-functioning instruments to measure HRQoL in these diseases. 
The overall objective of the present study was to contribute to increased use of HRQoL 
measures in clinical practice and cardiologic research through cultural and language 
adaptation of instruments, assessment of their psychometric properties and improved 
understanding of HRQoL following MI. To achieve this overall objective, the study had the 
following secondary goals: 
 
1. To translate and adapt a short questionnaire for patients with impaired heart 
function for use in Norwegian patients. 
2. To assess the reliability and validity of this questionnaire in patients with 
prior MI. 
3. To assess the reliability and validity of a short angina pectoris-specific 
questionnaire in Norwegian patients with prior MI. 
4. To compare HRQoL in patients 2.5 years after MI with an age- and sex-
adjusted Norwegian general population. 
5. To compare HRQoL 2.5 year after MI between men and women. 
6. To identify determinants for HRQoL 2.5 years after an MI in men and 
women separately. 
7. To assess the association of the LVEF measured during hospitalization for 
the index MI with subsequent HRQoL.  
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3 Study design and methods 
This study was based on a prospective observational cohort study including a cross-sectional 
postal survey of patients with previous MI recruited to the INfarction and PHARMacotherapy 
(INPHARM) study.  
The official clinical diagnoses were accepted without reassessment or revision. We used 
the following definition of MI [4]: 
1. Retrosternal pain with radiation to neck, arms or abdomen, independent of 
respiration. Duration at least 20 minutes and no or just transient effect of 
nitroglycerine. Accompanying, symptoms are: nausea, vomiting, cold sweat, 
anxiety, and dyspnoea or syncope/cardiac arrest. 
2. ST segment elevation in one or more leads. Negative T-wave development. 
After few hours up to 1–3 days development of Q-waves with transmural 
infarction. New left (or right) bundle branch block together with typical clinical 
signs. 
3. Creatinin kinase above 200 U/l for men and over 150 U/l for women. Creatinin 
kinase MB fraction over 10 microg/l. 
 
 
3.1 Data collection 
3.1.1 The INPHARM study 
The INPHARM study included patients with a discharge diagnosis of acute MI, defined as 
codes I21 and I22 in the ICD-10 (The International Statistical Classification of Diseases and 
Related Health Problems, tenth version). The INPHARM study included consecutive patients 
discharged alive or dead from 16 hospitals during 3- to 6-month periods between August 
1999 and January 2000. Patients who were dead before admission to the casualty department 
or who died before receiving any medical treatment, and patients who had their infarct during 
hospitalization for other conditions, were not included in this study. The following hospitals 
participated in the INPHARM study: Aker University Hospital, Oslo; Akershus University 
Hospital, Lørenskog; Diakonhjemmet Hospital, Oslo; Haugesund Hospital, Haugesund; 
Innlandet Hospital, Elverum; Innlandet Hospital, Gjøvik; Innlandet Hospital, Hamar; 
Innlandet Hospital, Kongsvinger; Innlandet Hospital, Lillehammer; Innlandet Hospital, 
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Tynset; Levanger Hospital, Levanger; Lovisenberg Diakonale Hospital, Oslo; Nordland 
Central Hospital, Bodø; Ullevål University Hospital, Oslo; Vestfold Hospital, Tønsberg; and 
Ålesund Hospital, Ålesund. A total of 901 patients were included in the study.  
One or two local cardiologists recorded a structured data set from the patient medical 
records. The data set included information on the medical history, presenting features, drugs 
used before admission, smoking habits, the LVEF measured during hospitalization, treatment 
received during hospitalization and drugs used at discharge. Cardiovascular drugs used at 
discharge were classified into the following 11 classes: aspirin, beta-blockers, regular 
nitrates, diuretics, calcium antagonists, ACE inhibitors, warfarin, digitalis, statins, 
angiotensin-II receptor antagonists and ticlopidine/clopidogrel. The indications for use were 
classified as secondary prevention, hypertension, angina pectoris, HF or other. The LVEF 
was classified as >50%, 40–50% and <40%. The data are presented in Appendix I. A 
physician collected the data within 6 months of hospital discharge.  
 
3.1.2 The postal survey 
At a mean of 2.5 years (range 2.1–3.1 years) after the index MI, we mailed a questionnaire to 
patients who were alive (according to the hospital information system and the national 
population register of Statistics Norway). Questionnaires were sent to the patients from the 
hospitals where they were discharged, with a cover letter signed by the head of the cardiology 
unit of the hospital. After 4 weeks we sent a reminder to non-respondents.  
 
3.1.3 Formal requirements 
The physicians collected the INPHARM study data after discharge to avoid interference with 
patient treatment. The Norwegian Data Inspectorate approved the establishment of the 
INPHARM database and gave a concession for the data to be used for 10 years. The Regional 
Committee for Medical Research Ethics and the Norwegian Data Inspectorate also approved 
the postal survey (Appendix II). The patients agreed to participate in the survey by 
responding to the questionnaire. 
We entered no personal identifiers into the databases. However, each head physician at 
the participating hospitals kept a paper list that linked the serial number in the study with 
information that identified each person.  
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3.1.4 The questionnaire 
The questionnaire consisted of several sections. In addition to HRQoL instruments, we asked 
about work status, cardiovascular events after the index MI, smoking habits and current 
medication. The HRQoL instruments included in the questionnaire are described below. The 
questionnaire is detailed in Appendix III.  
 
3.1.4.1 SF-36 
The SF-36 is a generic 36-item health status questionnaire that reports HRQoL on the 
following eight scales: Physical functioning, Role functioning-physical, Bodily pain, General 
health, Vitality, Social functioning, Role functioning-emotional, and Mental health [92-94]. 
The raw scores on these scales are transformed to a score from 0 to 100, with a higher value 
indicating a better level of functioning. The eight SF-36 scales are weighted and aggregated 
to two summary scales: the Physical component summary (PCS) and the Mental component 
summary (MCS) [132]. The PCS and MCS scores are reported on a standardized scale for 
comparison with a general US population with a mean score of 50 and a standard deviation 
(SD) of 10 [132]. The SF-36 has been extensively validated and used in patients with CAD 
[38;92;96;97;133-135]. We used the Norwegian standard SF-36, version 1.2 [136]. 
 
3.1.4.2 EQ-5D Index 
The EQ-5D is a generic HRQoL instrument consisting of five items: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. Each item is scored on 3-point scale: no 
problems (score of 1), moderate problems (2) and extreme problems (3). Responses to these 
items can be converted to a utility score, the EQ-5D Index, by applying time trade-off 
valuations obtained from the general population to each of the possible five-dimensional 
health state profiles. A score of 1.0 represents perfect health and 0 represents being dead 
(negative utilities are also possible, representing states perceived to be worse than being 
dead). We used a time trade-off tariff from a representative sample of the UK population 
[137]. The EQ-5D Index has high validity in post-MI patients [99;138;139]. 
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3.1.4.3 KCCQ 
The KCCQ is a 23-item questionnaire measuring HRQoL in patients with chronic HF 
regardless of aetiology [106]. Each item is scored on a 5-, 6- or 7-point scale [80]. The 
questionnaire assesses the following six domains of HRQoL: Physical limitation, Symptoms, 
Symptom stability, Social limitation, Self-efficacy and Quality of life. We calculated the 
score on each scale as the mean of the item scores, which was then transformed to a score 
from 0 to 100, with a higher score indicating a higher level of functioning. In addition, the 
KCCQ scales were aggregated into two summary scores: the Functional status summary 
score (the mean of the Physical limitation- and the Symptoms scale scores) and the Clinical 
summary score (the mean of the Physical limitation-, Symptoms-, Social limitation- and 
Quality of life scale scores) [106]. 
The culture and language of the KCCQ was adapted using a recommended procedure 
[79]. Two persons independently translated the questionnaire into Norwegian, with 
agreement on a consensus version reached after discussion with a third person. This version 
was then back-translated into English by a professional translator. Comparison of the back-
translated version with the original English version revealed only minor discrepancies which 
were rectified.  
 
3.1.4.4 SAQ 
The SAQ is a 19-item questionnaire measuring HRQoL in patients with CAD. The 
questionnaire assesses the following five domains of HRQoL: Physical limitation, Angina 
stability, Angina frequency, Treatment satisfaction, and Disease perception. Items are scored 
on 5- or 6-point scales. Each score on the five scales is calculated as the sum of item scores in 
the domain, which is then transformed to a score from 0 to 100 (with a higher score 
indicating a better level of function) by subtracting the lowest possible score, dividing by the 
range of the scale and multiplying by 100 [103]. The SAQ has been shown to be valid, 
reliable and sensitive [103;134;140]. It has been used to assess outcomes in clinical trials, 
predict events, measure quality of care and support patient management [141-145]. The 
questionnaire was translated using a recommended translation/back-translation process [79]. 
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3.2 Description of the material 
The material in the postal survey of the INPHARM study is presented in Fig. 3. One of the 
hospitals that participated in the INPHARM study, Innlandet Hospital, Tynset, did not 
participate in the postal survey. Three hundred and twenty-two patients died before the 
survey, and 15 patients were excluded for miscellaneous reasons. A total of 548 patients were 
eligible and were sent a questionnaire, of whom 408 (74%) responded. In the retest we 
mailed a second questionnaire to 100 respondents 4 weeks after receiving their first response. 
The response rate in the retest was 81%.  
 
 
 
 
Missing address, n = 8
Included in the postal survey, n = 548
Excluded for miscellaneous reasons, n = 7
Respondents, n = 408
INPHARM patients, n = 901
One hospital excluded, n = 16
Dead at the time of the postal survey, n = 322
Non-respondents, n = 140
 
Figure 3  Material of the INPHARM study and the postal survey 
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3.3 Statistical analysis 
We present descriptive statistics with mean and SD values or proportions, and for group 
comparisons we used t-tests, chi-square tests and Fischer’s exact tests as appropriate.  
Papers I and II describe how the test–retest reliability of the HRQoL scales in the 
KCCQ and the SAQ and summary scores of the KCCQ were determined using intraclass 
correlation coefficient (ICC) [79;146]. Test–retest analyses were performed using the scores 
of individual patient separated by a 4-week interval. We anticipated that the patients were in a 
stable phase and chose 4 weeks to minimize the recall of previous answers.  
We assessed construct validity in Papers I and II by assessing intercorrelations of 
corresponding scales and summary scores. Construct validity would be supported by the 
correlation between scales measuring related phenomena being higher than that between 
unrelated scales. We quantified the correlation coefficients using previous nomenclature on 
agreement statistics: substantial (0.61–0.81), moderate (0.41–0.60) and fair (0.21–0.40) 
[147]. 
We assessed criterion-related validity by investigating the capability of the scales and 
summary scores of the KCCQ and SAQ to differentiate between groups defined by a criterion 
with expected differences in HRQoL. We used criteria from the literature, and general 
knowledge about and availability of disease characteristics to define groups. Paper I describes 
the use of medication at discharge that was prescribed for HF, and the LVEF as a criterion for 
assessing the validity of the KCCQ scales and summary scores. Paper II uses concurrent 
long-acting nitroglycerine and sublingual nitroglycerine as proxies for moderate and severe 
angina, respectively, as criteria for assessing the validity of the SAQ scales. 
Papers III and IV use multiple linear regression to detect determinants of the two SF-36 
summary scales, and of the KCCQ clinical summary and EQ-5D index, respectively. Papers 
III and IV use method enter and forward stepwise multiple regression analysis, respectively.  
Paper III compare SF-36 scores in our sample of patients with previous MI with 
general-population norms [136]. To do this we computed new variables for each SF-36 scale 
for the individual patient, with these new variables being the difference between the observed 
score for each subject and the age- and sex-specific general-population norm. Comparisons 
with the general population were then performed using one-sample t-tests with Bonferroni 
corrections for multiple comparisons. 
We compared scores on the HRQoL scale between groups of patients using analysis of 
covariance whilst adjusting for background variables such as age, sex and education. 
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Adjusted scores were presented as estimated marginal means. We used SPSS (SPSS, 
Chicago, IL) statistical software for all statistical analysis.  
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4 Results and general discussion 
4.1 Summary of results 
4.1.1 Paper I 
Background: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a recently 
developed disease-specific instrument for measuring health-related quality of life in patients 
with chronic heart failure regardless of aetiology. 
Aim: To assess the reliability and validity of the KCCQ in patients with previous myocardial 
infarction. 
Methods and Results: In 754 patients with myocardial infarction discharged alive, we 
collected clinical data from the patients’ medical records. Two and a half years after the acute 
myocardial infarction, we mailed a self-administered questionnaire to the 548 patients still 
alive. The response rate was 74%. Internal consistency reliability, assessed with Cronbach’s 
α, ranged 0.66-0.95. Test-retest reliability, tested with an intraclass correlation coefficient, 
ranged 0.41-0.83. The pattern of association between similar and dissimilar scales of the 
KCCQ and SF-36 supported the convergent/divergent validity of the KCCQ. Four of the 
KCCQ scales and the two summary scores discriminated between patients with and without 
medication for heart failure, and between different levels of left ventricular ejection fraction 
supporting different groups validity. 
Conclusions: The Norwegian version of the KCCQ showed acceptable reliability and cross-
sectional validity, which support the use of this questionnaire to measure health-related 
quality of life after myocardial infarction. 
 
4.1.2 Paper II 
The aim of this study was to validate the Norwegian version of the Seattle Angina 
Questionnaire (SAQ), a self-administered 19-item questionnaire designed to assess health-
related quality of life in patients with chest pain or coronary artery disease. In 885 patients 
with prior myocardial infarction (MI), we abstracted clinical data from the patients’ medical 
records. Two to three years after the MI, we mailed a self-administered questionnaire 
including the SAQ, the Short Form 36 (SF-36), and questions about current medication, to 
the 548 patients still alive. The response rate was 74%. Internal consistency reliability of the 
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SAQ, assessed with Cronbach’s α, ranged 0.75–0.92. Test-retest reliability, tested with an 
intraclass correlation coefficient, ranged 0.29–0.84. The pattern of association between 
similar and dissimilar scales of the SAQ and SF-36 mainly supported the construct validity of 
the SAQ. Four of the five SAQ scales discriminated between patients with different 
medication regimens as a proxy for severity of angina pectoris. We conclude that the 
Norwegian version of the SAQ showed acceptable reliability and cross-sectional validity 
following MI, with properties in line with the original US version.  
 
4.1.3 Paper III 
Background: The role of sex differences in health-related quality of life (HRQoL) after 
myocardial infarction (MI) remains controversial.  
Methods: In total 408 Norwegian patients completed the Short Form 36 (SF-36) 
questionnaire 2.5 years after MI. We compared HRQoL between sexes and with national 
norms. Multiple linear regression analysis was used to explore the association of scores on 
the Physical (PCS) and Mental (MCS) component summary scales with clinical and 
sociodemographic variables.  
Results: Women scored lower than norms on the Physical functioning, Role functioning-
physical, General health, and Role functioning-emotional scales. Men scored higher on 
Bodily pain, and lower on the other 7 scales compared to norms. Women <70 years scored 
lower than men on 3 out of 8 scales and on PCS. Women ≥70 scored lower than men on 5 out 
of 8 scales and on PCS. Relative to sex- and age-specific norms, there were no sex-
differences in SF-36 scores. Age, time since the index MI, chronic obstructive pulmonary 
disease (COPD), previous MI, and stroke predicted PCS scores in women. Education, COPD, 
infarct localization, number of indications for cardiovascular medication at discharge, 
medication for heart failure, and subsequent MI predicted PCS scores in men. Smoking 
status, education, and Q-wave MI were determinants for MCS scores in men.  
Conclusion: Patients had impaired HRQoL compared to sex- and age-specific norms 2.5 
years after MI. Women had lower HRQoL scores than men, but relative to norms HRQoL 
was equally affected in both sexes. Men and women had different determinants of HRQoL. 
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4.1.4 Paper IV 
Background: The objective was to explore the relationship between left ventricular ejection 
fraction (LVEF) assessed during hospitalization for acute myocardial infarction (MI) and 
later health-related quality of life (HRQoL). 
Methods: We used multivariate linear regression to assess the relationship between LVEF 
and HRQoL in 256 MI patients who responded to the Kansas City Cardiomyopathy 
Questionnaire (KCCQ) and the EQ-5D 2.5 years after the index MI. 
Results: 167 patients had normal LVEF (>50%), 56 intermediate (40%–50%), and 33 
reduced (<40%). The mean (SD) KCCQ clinical summary score was 85 (18), 75 (22), and 68 
(21) (p<0.001) in the three groups, respectively, and the corresponding EQ-5D Index scores 
were 0.83 (0.18), 0.72 (0.27), and 0.76 (0.14) (p=0.005). In multivariate linear regression 
analysis age ≥70 years, known chronic obstructive pulmonary disease, subsequent MI, 
intermediate LVEF, and reduced LVEF were independent predictors of reduced KCCQ 
clinical summary score. Female sex, medication for angina pectoris at discharge, and 
intermediate LVEF were independent predictors of reduced EQ-5D Index score. 
Conclusions: LVEF measured during hospitalization for MI was a predictor for HRQoL 2.5 
years later. 
 
 
4.2 Methodological considerations  
4.2.1 Patients 
The patient sample in the INPHARM study can be regarded as representative of Norwegian 
MI patients, since consecutive MI patients were included, hospitals recruited patients over 
similar time periods and a wide range of hospitals (both teaching and non-teaching) in 
different geographic regions participated. Also, the 548 patients included in the postal survey 
were regarded representative of patients surviving 2–3 years after their MI.  
Table 2 in Paper I compares respondents and non-respondents in the survey. Non-
respondents were more likely to be female, and were older, had more cardiovascular 
diagnoses before the index MI and were discharged with less medication primary prescribed 
for secondary prevention and more medication prescribed for HF. Also, the LVEF tended to 
be lower in non-respondents. These results indicate that the CVD burden was higher for non-
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respondents than for respondents, which might have influenced the HRQoL scores, especially 
on scales assessing physical health.  
Our response rate of 74% is comparable to response rates of 74–89% in other studies 
[38;114;115;118;119;121;148]. The two studies with the highest response rates used the SF-
36 2 and 4 years after an index MI [38;115]. The youngest patients in our study scored higher 
and the older patients comparable to age-matched patients in the study that assessed HRQoL 
4 years after MI [38], and the scores of our patients were comparable to patients in the study 
on HRQoL 2 years after MI [115]. However, the latter study included only patients with a 
first MI [115].  
 
4.2.2 Design and data collection 
While the INPHARM study was a cross-sectional survey, the follow-up study was a 
prospective observational cohort study [149]. However, we only assessed HRQoL in the 
patients once. We do know the HRQoL of the patients at a mean of 2.5 years after the index 
MI, but we do not know their HRQoL prior to the MI. Therefore, we do not know the 
changes in HRQoL. To determine whether there is a causal relationship between 
determinants and HRQoL, such possible determinants should be related to changes in 
HRQoL between before and after the MI. The time lag between the clinical variables 
registered at the time of the MI and assessment of HRQoL has implications for the direction 
of an observed association. For example, a reduced HRQoL does not cause a reduced LVEF.  
When we planned the study, there were reports on HRQoL at 6 months, 1 year, 2 years, 
4 years and 5 years after an index MI, but no studies for the period between 2 and 4 years 
[36;38;118;120;122;127;148]. At 2 to 3 years after the MI we would expect the patients to be 
in a stable phase, and that most of the expected improvement after the MI was achieved.  
In the INPHARM study, local physicians collected clinical data, data on in-hospital 
treatment and medication at discharge, and the study thus involved several persons, most of 
who were cardiologists. All of the physicians had experience in handling heart patients and 
were familiar with the local medical records, routines and guidelines, which should have 
improved the completeness and reliability of the data. Information on the indication for drug 
use at discharge was also collected from the medical record, but this is not always clearly 
stated in a patient’s records. Many cardiovascular drugs have more than one indication for 
use. The main indication for use was sought, but identifying this retrospectively can be 
difficult and require interpretation by the individual clinician.  
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In the postal survey patients reported their medication use in the questionnaire. We did 
not compare this with drug lists in the hospital records. However, a recent study found good 
agreement between patient-reported medication use and information in their medical records 
[150].  
The hospital diagnosis of MI was accepted without reassessment or revision, and all 
hospitals used the same definition of acute MI [4]. The criteria for diagnosing MI were 
changed in 2000, shortly after the patients in our study had been diagnosed. The new MI 
definition has placed more emphasis on biochemical markers and less on clinical parameters 
and ECG, which has resulted in an increased incidence of small MIs, with some patients who 
had previously been diagnosed as unstable angina or angina pectoris now being diagnosed as 
MI. It is not obvious how this change in patient population has influenced HRQoL among MI 
patients. In a study on HRQoL in ACS that analyzed patients in 1998 and 1999 (and thus 
using the same definition for acute MI as in the present study), a discharge diagnosis of 
unstable angina was a predictor of a reduced SF-36 PCS score [151]. To my knowledge, no 
reports on intermediate- or long-term HRQoL after MI using the new diagnostic criteria have 
been published so far. 
 
4.2.3 HRQoL instruments 
There are disease-specific instruments such as the MacNew QLMI questionnaire that cover 
the major domains of HRQoL following MI without reporting HRQoL separately with regard 
to the most common heart-specific complications following MI; that is, chest pain or HF 
[102]. To improve the relevance of our study to clinical cardiology, we decided to use 
separate instruments for HF and angina pectoris, and chose instruments that included the 
symptom frequency and severity. Frequently MI also affects mental well-being. Therefore, to 
cover most of the effects of an MI on the health status, we also included an instrument 
assessing mental health status. We chose the Hospital Anxiety and Depression scale, which is 
a 14-item self-administered instrument assessing anxiety and depression in patients with 
somatic diseases [152]. This scale has been translated into Norwegian and used in patients 
with heart diseases [153-155]. The SF-36 was the first-choice generic instrument, since it is 
widely used, has high reliability and validity in patients with CAD, and reference values are 
available for a Norwegian general population [97;136]. The second generic instrument 
included in the questionnaire, the EQ-5D index, was attractive due both to its brevity and the 
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possibility of converting it into a utility score [137;139;156]. EQ-5D has also been found to 
be reliable and valid in patients with MI [99].  
The SAQ, KCCQ and SF-36 are all HRQoL instruments covering the most common 
domains of HRQoL. Combining these instruments in the same questionnaire provided 
detailed information on how angina pectoris, HF and general health affect HRQoL after MI, 
with the possibility to compare and analyze differences and variations. However, we do not 
know how repeated questions on the same subjects influence the responses, even though the 
patients were told to consider each item with regard to chest pain or HF, for example.  
 
4.2.4 Statistical considerations 
It has often been discussed whether to use parametric or non-parametric statistical methods 
when investigating quality of life. The individual item responses collected in assessments of 
HRQoL are most often ordinal or nominal data. Such item responses are often aggregated to 
scales, which are analyzed further with the assumption that the aggregates now have interval 
properties and are normally distributed. This can be an invalid assumption. Some of the non-
parametric methods are difficult to apply, and hence researchers often use standard 
parametric methods. This is also the case in other areas of research in medicine and 
psychology. A survey of 175 papers using ordinal data found that at least 75% of them used 
statistical methods that assumed a measurement scale with interval or ratio properties [157].  
How to specify models in multiple regression analysis and whether it is feasible to use 
automated models for variable selection also needs to be considered [158]. Paper III describes 
the manually building of multivariate models based on a-priori-determined criteria. Paper IV 
describes stepwise forward variable selection. In both instances variables were restricted in 
advance, based on findings in the literature and on their availability in our sample. 
 
4.2.5 Ethics 
Both the INPHARM study and the HRQoL postal survey were approved by the Regional 
Committee for Medical Research and the Norwegian Data Inspectorate. The data in the 
INPHARM study were collected after the patients were discharged. Therefore, none of the 
clinicians was aware of the study when patients were in hospital for their index MI. Thus, the 
INPHARM study did not interfere with in-hospital treatments of MI. However, the design of 
the study did not allow patients to exclude themselves from the cohort. 
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Patients were not aware of the HRQoL postal survey before they received an invitation 
to participate and orientation about the survey signed by the head of the cardiology section or 
department together with a supplementary letter from the researchers and the questionnaire. 
Therefore, the invitation to participate in the survey could have been an unpleasant reminder 
of what the patients might have regard as a closed book, especially for those without 
symptoms from their CAD and with normal physical function. However, the high response 
rate indicates that this approach was generally accepted. 
A few of the questionnaire items could have been regarded as offensive by some 
patients, such as item 15 in the KCCQ that asks about “intimate relationships with loved 
ones”. This or other items could have led to patients feeling that their privacy was violated, 
resulting in them not returning the completed questionnaire or not responding to that specific 
question. Indeed, only 28% of our respondents provided a valid response to this item. The 
rate of single-item non-response was 10–16% on three other items asking about working-, 
leisure- and social activities.  
 
 
4.3 Discussion of the main results 
4.3.1 Reliability and validity of the instruments 
As expected, the patients in our study scored substantially higher on all KCCQ scales, and 
had a relatively high ceiling effect (13–36%) on the different scales compared to patients with 
known HF [106]. Our patients also scored higher than patients with stable angina on four out 
of five scales of the SAQ [103;159]. One of the inclusion criteria in the study of angina 
pectoris by Spertus et al. was current prescription of nitroglycerine [103]. The scores on the 
SAQ scales of patients in that study were comparable to the scores of those patients in our 
study who reported that they used nitroglycerine (Table 5 in Paper II). Acceptability of the 
translated instruments among patients in our study was satisfactory, with >90% and 89–97% 
scorable multi-item scales for the KCCQ and SAQ, respectively. In our study the internal 
consistency reliability of the KCCQ scales equaled that of the original version of the KCCQ, 
with values of >0.70 on all scales except Self-efficacy. For the Norwegian translation of the 
SAQ, all the Cronbach’s α values were >0.80. The test–retest reliability as quantified by ICC 
for the KCCQ was >0.70 on all scales and summary scores except Symptom stability, Self-
efficacy, and Quality of life. The ICC was >0.70 on all scales of the SAQ except Angina 
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stability. It has been suggested that HRQoL instruments can be used for comparisons at the 
group and individual patient levels when the reliability is >0.70 and >0.95, respectively 
[79;160]. Acceptable reliability for comparisons at the group level were obtained when these 
criteria were applied to the Norwegian translations, the SAQ scales Physical limitation, 
Angina frequency, and Treatment satisfaction, and the KCCQ scales and summary scores 
Physical limitation, Symptoms, Social limitations, KCCQ Functional Status, and KCCQ 
Clinical Summary. However, none of the scales fulfilled the criteria for use at the individual 
level.  
The discriminatory capacity was higher for the KCCQ than for the generic SF-36 
instrument for all scales except the Symptom stability and Self-efficacy. However, the SF-36 
has a broader scope, and hence supplements the KCCQ. These results support the construct 
validity of both the KCCQ and SF-36 in patients with previous MI. The SF-36 has previously 
shown high validity in patients with CAD, but this has not been tested for the Norwegian 
translation [97]. The KCCQ was developed in patients with HF but is relevant to a substantial 
proportion of MI patients, and our results support its validity in unselected patients with 
previous MI. 
We assessed convergent/divergent validity, which is an aspect of construct validity, 
using a multitrait-multimethod matrix. For the KCCQ all predicted substantial correlations 
between KCCQ scales and summary scores and SF-36 scales were ≥0.56. The criterion for a 
substantial correlation is considered to be 0.60, and this was satisfied for 16 of the 20 
predicted correlations [147]. For the SAQ, 9 of the 13 predicted correlations were >0.54 and 
6 were >0.60. We used medication for HF at discharge and current antiangina medication as 
criteria for different group validity [161]. All scales and summary scores of the KCCQ except 
Symptom stability and Self-efficacy performed well, as did all SAQ scales except Angina 
stability, indicating high validity of the two instruments.  
Our cross-sectional study could not assess responsiveness. The KCCQ has been shown 
to have better responsiveness than the MLHF and to reflect clinical changes in HF patients 
better than the NYHA classification and 6-minute walk test [106;162]. However, the 
responsiveness of the KCCQ needs to be assessed also in patients with previous MI. The 
SAQ has been shown to be responsive in patients with CAD, but like the KCCQ needs to be 
tested separately in patients with MI [103;140]. 
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4.3.2 Comparisons with the general population and patients with other 
diseases 
The scores of our patients were significant lower than those of sex- and age-adjusted norms 
on all SF-36 scales except Bodily pain (Table 3 in Paper III) [136]. A difference in score of 5 
or more on the SF-36 scales from 0 to 100 is often regarded as clinically significant [133]. 
Applying this criterion conservatively, we found a clinically significant reduced score on the 
scales of Physical functioning, Role functioning–physical, General health and Role 
functioning–emotional. However, the scores exhibited only moderate differences between our 
patients and the general-population norms, being less than 10 on most scales. Still, given the 
high prevalence of previous-MI patients in the general population, a reduced HRQoL in MI 
patients represents a substantial societal health problem.  
The difference in score between previous-MI patients and norms was generally the 
same in both men and women, and in patients below and above 70 years. Our results are 
consistent with most studies finding that MI reduces HRQoL compared to norms, at least 
until 5 years after the index MI [38;113-116;163].  
The differences in SF-36 score between previous-MI patients and sex- and age-adjusted 
norms in our study were smaller than the differences reported by Brown et al. in MI patients 
younger than 65 years assessed 4 years after their index MI [38]. The patients in that study 
had experienced their index MI approximately 7 years before the patients in our study, and 
during which drug therapies improved and aggressive interventions became more common 
[17]. This might have contributed to the better results in our study.  
HRQoL scores in patients with cardiovascular conditions are reported to be comparable 
to those for other chronic conditions such as cancer and chronic respiratory diseases, but 
higher than those in patients with musculoskeletal, renal, gastrointestinal, cerebrovascular or 
neurological conditions [38;113-116;163].  
 
4.3.3 Determinants of HRQoL 
Different determinants and predictors of HRQoL following MI have been identified. The 
predictors have varied between studies depending on factors such as patient selection, the 
possible predictor variables included, the applied HRQoL instrument and the time interval 
between the index MI and HRQoL assessment.  
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In a systematic review on 11 studies published before 1999, Simpson and Pilote found 
that the most significant predictors of HRQoL after MI were the severity of persistent 
symptoms such as dyspnoea or chest pain, the patient’s age, and the timing of HRQoL 
measurements [109]. Two more recent studies by Beck et al. (on patients with MI) and 
Rumsfeld et al. (on patients with ACS) both concluded that non-cardiac factors were the most 
powerful predictors of subsequent HRQoL [118;151]. The latter study measured HRQoL 7 
months after the index hospitalization, and identified both previous CVD (e.g. prior CABG 
surgery and HF) and also non-CVDs such as depression, arthritis, COPD (chronic obstructive 
pulmonary disease), diabetes mellitus, previous peptic ulcer disease, reduced kidney function 
and stroke as predictors of HRQoL as measured by the SF-36 PCS or MCS [151]. They also 
identified revascularization – both during the index hospitalization and after discharge – as 
positive predictors of HRQoL. Beck et al. measured HRQoL both during hospitalization and 
after 1 year, with the baseline HRQoL used as an independent variable in the analysis of 
determinants for HRQoL [118]. In addition to baseline HRQoL, only age, sex and previous 
CABG surgery were associated with the PCS score at 1 year. The presence of depression at 
the time of the index MI was the only predictor of MCS other than the baseline score. 
Including baseline HRQoL in the analysis accounted for much of the comorbidity that 
otherwise might have been an important predictor. This latter study actually analyzed 
predictors of recovery after MI. The social network has also been identified as a predictor of 
the long-term MCS score [121].  
The design of our study was the same as that of Rumsfeld et al., with HRQoL measured 
once only, and thus HRQoL in our study might have been affected by previous health 
conditions, factors associated with the index MI, and subsequent events [151]. We applied 
separate analyses to men and women (Table 4 in Paper III), which indicated that the 
predictors among men were the total number of indications for cardiovascular drugs at 
discharge and medication for HF at discharge. The number of cardiovascular indications for 
treatment at discharge was influenced both by previous CAD and the index MI, which cannot 
be distinguished. In women, previous MI, previous stroke and COPD were all associated with 
a lower PCS score. 
Among men, there was a clinically and statistically significant association between 
localization of the index MI and long-term HRQoL [133]. To our knowledge no previous 
study has shown this association, possibly because none of them applied separate analyses to 
the two sexes. Alternatively, a separate underlying cause (e.g. undetected previous MIs) 
could explain both the difficulty of localizing the index MI and the reduced HRQoL. In men, 
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but not in women, subsequent MI was associated with a reduced PCS score. However, this 
might be related to reduced statistical power, as only 3% of the women in our study reported 
new MIs.  
In our study age was associated with HRQoL only in women (Table 4 in Paper III). 
This was somewhat surprising considering that in the Norwegian national norms there is an 
age-related decrease in score on the four SF-36 scales that is associated most strongly with 
physical health, with the decrease appearing in the sixth decade in men and in the seventh 
decade in women [136]. This age-dependent decrease in HRQoL in the general population 
might be attributable to ageing per se, due to decreased physical capacity, increased total 
burden of disease or reduced social support [131;164]. In addition, elderly subjects with MI 
have increased incidences of pre-MI CAD, reduced heart function, atrioventricular 
conduction disturbances, atrial fibrillation and diabetes mellitus, all of which might affect 
HRQoL. The age-dependent decrease in HRQoL in the general population indicates that not 
evaluating age as a determinant of HRQoL in patients with MI might lead to an 
overestimation of the effect of an MI in elderly patients or an underestimation of the effect in 
younger patients.  
 
4.3.4 Sex difference in HRQoL after MI 
We observed that the unadjusted HRQoL scores differed between men and women (with the 
lowest scores in women) on many of the SF-36 scales both for patients younger and older 
than 70 years (Table 2 in Paper III). There are at least three theoretical health-related 
explanations for a sex difference in HRQoL scores after MI [165]. First, they might be due to 
CAD being more severe in women than in men. Second, women might have more premorbid 
comorbidities or a lower functional level, with the observed differences thus being due to 
existing sex differences in the general population. Third, women might have poorer recovery 
after an MI compared to men, which is supported by one study finding that the recovery in 
the first year after an MI was worse in women than in men on several SF-36 scales [166]. A 
fourth, more methodological explanation of observed sex difference in HRQoL is that the 
employed HRQoL instrument favours aspects of HRQoL for which men generally have a 
higher functional level than women. For example an instrument which emphasizes physical 
function and symptoms would lead to this type of sex-difference. Men generally have higher 
physical function than women, and it has been suggested that men are socialized to ignore 
physical discomfort and thus are unaware of symptoms women feel keenly [167]. There is 
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research evidence supporting all of the health-related explanations. CAD is diagnosed later in 
women than in men, and therefore women have a longer period without treatment, which 
would result in a more severe status when the condition is finally diagnosed.  
When interpreting observed sex differences in SF-36 scores in patients, it must be noted 
that men in the general population score higher than women at the same age on most SF-36 
scales [133;136]. We accounted for this sex difference in general-population norms when 
comparing scores on SF-36 scales between male and female patients by computing new 
variables for each SF-36 scale defined as the difference between the observed score for each 
respondent and the age- and sex-specific general-population norm. Applying these new 
variables revealed no sex difference in scores on SF-36 scales in post-MI patients beyond the 
sex difference in the general population, and hence the sex differences in scores on SF-36 
scales in our study are likely to simply reflect differences in the general population.  
 
4.3.5 LVEF and HRQoL 
The LVEF is an important predictor of survival in patients with heart disease and is the most 
commonly used non-invasive measure of cardiac function [31;168;169]. The LVEF is a 
measure of left ventricular systolic function, with its value being an important indicator of the 
amount of heart muscle loss during an MI. However, other factors such as diastolic function, 
valvular heart disease, dyssynchronicity or arrhythmias can all impact on the overall function 
and physical capacity of the heart. More composite measures of a patient’s physical function, 
such as a 6-minute walk test, will be influenced by lung function, muscle strength and 
diseases affecting the locomotor system. Similarly, these conditions will also influence the 
NYHA classification. Further, physical functioning is only one of multiple domains 
contributing to the construct HRQoL. Therefore, the association between the LVEF and 
HRQoL is not obvious, and this explains why studies involving patients with previous MI 
both have and have not observed an association between the LVEF and HRQoL 
[115;117;119;170-177].  
In our study we identified a moderate but highly statistically significant association 
between the LVEF measured during hospitalization for the index MI and HRQoL about 2.5 
years later, after controlling for other variables (Table 3 in Paper IV). A moderate association 
between the LVEF and HRQoL would be expected from the conceptual model of Wilson and 
Cleary [70] that illustrates the presence of multiple links between physiological measures and 
HRQoL, and hence that HRQoL can be influenced by diverse factors.  
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4.3.6 Limitations  
In each of Papers I–IV we have reviewed the limitations of the analyses and the uncertainty 
of the study, including the response rates, the possibility of multiple indications for 
cardiovascular drug treatment at discharge, the use of different methods to assess the LVEF 
and problems with reliability when data were collected by multiple clinicians. Other 
limitations relate to the study design with HRQoL measured once only.  
The change in the diagnostic criteria for MI in Norway in 2000, lead to an increased 
number of MIs being diagnosed. The disease entity ACS – which comprises ST-segment 
elevation MI, non-ST-segment elevation MI and unstable angina – is increasingly used in 
clinical practice. Caution is required when generalizing results obtained in patients diagnosed 
according to the WHO definition to patients diagnosed with the new MI criteria or to patients 
with ACS.  
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5 Conclusions and future perspectives 
5.1 Conclusions 
 This study has validated the Norwegian translations of two heart-specific HRQoL 
instruments, which will facilitate the use of these instruments in Norwegian patients 
without a long documentation process. Our results also support the validity of the 
Norwegian translation of the SF-36 in patients with previous MI.  
 We have identified that HRQoL in both men and women is lower about 2.5 years after 
an MI than in age- and sex-matched Norwegian norms.  
 Given the existing difference in scores between men and women in the general 
population, HRQoL was equally affected after MI in the two sexes. This implies that 
caution is required when directly comparing HRQoL between the sexes. 
 We have presented and applied a statistical method for comparing SF-36 scores 
between groups of patients that takes into account general-population scores. 
 We have demonstrated that HRQoL about 2.5 years after an MI is more closely 
associated with features of the index MI in men than in women.  
 In patients with acute MI, heart function during hospitalization – as measured with the 
LVEF – showed a moderate but statistically significant association with long-term 
HRQoL.  
 
 
5.2 Future perspectives 
While the original SAQ and KCCQ have shown good results [103;106;140], the 
responsiveness of their Norwegian translations needs to be tested, such as in stable angina 
patients undergoing planned PCI and in HF rehabilitation clinics, respectively.  
To facilitate the use of HRQoL measures in clinical practice, it would be useful to have 
instruments that can be applied longitudinally to individual patients. HRQoL measures need 
to exhibit sufficient validity and reliability in individual patients before they can be used in 
clinical practice. Applying HRQoL regularly to individual patients will improve the accuracy 
of doctor–patient communications and thus could contribute to improved treatment. The 
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further development of instruments to achieve this should be a top priority of HRQoL 
research in patients with CAD.  
Whether future studies should use generic or disease-specific HRQoL instruments 
depends on the purpose of each study. When assessing the effect of an intervention it is 
feasible to use measures that are most sensitive to change, which frequently is a disease-
specific instrument. However, generic measures must be used if the purpose is to compare 
patients with different diseases or with the general population. Often a survey aims at both, 
and hence a common recommendation is to use both a generic and a disease-specific 
instrument.  
Wilson and Cleary have presented a general conceptual model linking clinical variables 
with HRQoL that takes into account characteristics of the individual and the environment 
[70]. This model can serve as a basis for testing the relationship between sets of clinical 
variables, measures of heart function and HRQoL in patients with CAD. Formally testing an 
a priori model in any appropriately designed study will improve the knowledge of how 
potential determinants of HRQoL relate to different aspects of HRQoL and quality of life, 
and also how the determinants are interrelated. A better understanding of the interrelation of 
possible predictors of HRQoL could lead to an increased awareness of potentially modifiable 
determinants, better tailored treatment and at the same time a more holistic care for patients 
with CAD.  
HRQoL has been found to be a predictor of survival in patients with heart disease 
[87;142;178;179]. A better understanding of the association between HRQoL and survival 
could contribute to improved treatment. For example, will treatments that improve HRQoL 
also improve survival?  
The new diagnostic criteria for MI have reduced the distinction between MI and 
unstable angina, and the term ACS is now more commonly used. A longitudinal cohort study 
comprising a broad spectrum of ACS patients and with the intention to measure both the 
short- and long-term HRQoL, together with death and hospital admissions, would be very 
useful for understanding all aspects of the course of ACS.  
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